Brendan M. Weiss
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments 48
- Hematopoietic Stem Cell Transplantation 6
- Oncology top 1%
- Peptidase Inhibition and Analysis 12
- Cancer Treatment and Pharmacology 8
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 13
- Nephrology top 2%
- Parathyroid Disorders and Treatments 8
- Molecular Biology top 2%
- Amyloidosis: Diagnosis, Treatment, Outcomes 34
- Protein Degradation and Inhibitors 11
- Co-authors
- Ola LandgrenRobin HowardTahamtan AhmadiDan T. VoglJude AbadieAdam D. CohenW. Michael KuehlEdward A. Stadtmauer
- Cited by
- HematologyOncologyGenetics
- Journals
- New England Journal of Medicine (1 paper)Journal of Clinical Investigation (1 paper)Journal of Clinical Oncology (12 papers)
- Partner nations
- United StatesNetherlandsItaly
In The Last Decade
Brendan M. Weiss
92 papers receiving 4.8k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Hematology 2.8k
- Oncology 2.2k
- Genetics 840
- Nephrology 387
- Molecular Biology 2.6k
Countries citing papers authored by Brendan M. Weiss
This map shows the geographic impact of Brendan M. Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendan M. Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendan M. Weiss more than expected).
Fields of papers citing papers by Brendan M. Weiss
This network shows the impact of papers produced by Brendan M. Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendan M. Weiss. The network helps show where Brendan M. Weiss may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Brendan M. Weiss, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2022 | 12 | |
| 3 | 2021 | 1 | |
| 4 | 2020 | 5 | |
| 5 | 2020 | 1 | |
| 6 | 2018 | 85 | |
| 7 | 2017 | 15 | |
| 8 | 2017 | 8 | |
| 9 | 2017 | 23 | |
| 10 | 2017 | 5 | |
| 11 | 2016 | 147 | |
| 12 | High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia. | 2016 | 35 |
| 13 | 2016 | 1 | |
| 14 | 2015 | 165 | |
| 15 | 2011 | 12 | |
| 16 | 2010 | 11 | |
| 17 | 2009 | 152 | |
| 18 | 2007 | 19 | |
| 19 | 2005 | 34 | |
| 20 | 1993 | 2 |
About Brendan M. Weiss
Brendan M. Weiss is a scholar working on Hematology, Genetics and Nephrology, having authored 94 papers that have together received 4.9k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (48 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (34 papers), Chronic Lymphocytic Leukemia Research (13 papers), Peptidase Inhibition and Analysis (12 papers), Protein Degradation and Inhibitors (11 papers), Parathyroid Disorders and Treatments (8 papers), Cancer Treatment and Pharmacology (8 papers) and Hematopoietic Stem Cell Transplantation (6 papers). The work is most often cited by research in Hematology (2.8k citations), Oncology (2.2k citations) and Genetics (840 citations). Brendan M. Weiss has collaborated with scholars based in United States, Netherlands and Italy. Frequent co-authors include Ola Landgren, Robin Howard, Tahamtan Ahmadi, Dan T. Vogl, Jude Abadie, Adam D. Cohen, W. Michael Kuehl, Edward A. Stadtmauer, Alfred L. Garfall and Torben Plesner. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.